| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Bauer Jake | Director | BRIDGEBIO ONCOLOGY THERAPEUTICS, INC., 256 EAST GRAND AVENUE, SUITE 104, SOUTH SAN FRANCISCO | /s/ Aaron Chan, Attorney-in-Fact | 2025-08-28 | 0001654909 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | BBOT | Stock Option (Right to Buy) | Award | $0 | +138K | $0.00 | 138K | Aug 26, 2025 | Common Stock | 138K | $9.59 | Direct | F1 |
| Id | Content |
|---|---|
| F1 | A fraction of the shares underlying such option equal to (x) the number of full months between April 25, 2025 ("Vesting Commencement Date") and the date on which a registration statement on Form S-8 is filed and effective with the Securities and Exchange Commission (the "S-8 Filing Date") divided by (y) 48 shall vest on the S-8 Filing Date, and 1/48th of the shares underlying such option shall vest each month thereafter on the day of the month corresponding to the Vesting Commencement Date (and if there is no suchcorresponding day for a month, then the vesting date shall be the last day of the applicable month) until 100% of the shares underlying such option is vested on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous service the Issuer on each such vesting date. |